Attached files
| file | filename |
|---|---|
| EX-32.1 - EX-32.1 - MERRIMACK PHARMACEUTICALS INC | mack-ex321_9.htm |
| EX-31.2 - EX-31.2 - MERRIMACK PHARMACEUTICALS INC | mack-ex312_8.htm |
| EX-31.1 - EX-31.1 - MERRIMACK PHARMACEUTICALS INC | mack-ex311_10.htm |
| EX-3.1 - EX-3.1 - RESTATED CERTIFICATE OF INCORPORATION, AS AMENDED - MERRIMACK PHARMACEUTICALS INC | mack-ex31_142.htm |
| 10-Q - 10-Q - MERRIMACK PHARMACEUTICALS INC | mack-10q_20180630.htm |
Exhibit 32.2
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report on Form 10-Q of Merrimack Pharmaceuticals, Inc. (the “Company”) for the period ended June 30, 2018 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Jean M. Franchi, Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that to her knowledge:
(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
|
Date: August 7, 2018 |
|
/s/ Jean M. Franchi |
|
|
|
Jean M. Franchi |
|
|
|
Chief Financial Officer |
|
|
|
(Principal Financial Officer) |